Number of RPG Awards
Includes Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Awards.
FY 2020 - 2023 Includes Cancer Moonshot Funding℠
The interim FY 2025 R01 payline, which was established while the Institute was operating under a continuing resolution, was rescinded. No official R01 payline was established for FY 2025. In addition, an NIH multi-year funding policy was implemented in that fiscal year that allowed several RPG competing awards to be funded for the entire project period upfront. Due to these policy changes, the FY2025 awards are not comparable to those of previous fiscal years
RPGs Summary, Fiscal Years 2024-2025
Over 77.2% of competing dollars supported grants that were awarded within the established payline, as well as RFAs; the remainder of the funds supported grants that exceeded the fundable range.**
RFA funds accounted for 12.4% of the FY 2024 competing dollars.
A total of 964 competing RPGs were funded.
| RPG Awards Funded | 2024 No. or % | 2024 Amount | 2025 No. or % | 2025 Amount |
|---|---|---|---|---|
| Total Funding for RPGs | 5,739 | $3,129,796 | 5,401 | $3,413,422 |
| SBIR/STTR | 199 | $158,454 | 226 | $181,570 |
| Funding for RPGs without SBIR/STTR Program | 5,540 | $2,971,342 | 5,175 | $3,122,667 |
| Continuation or Noncompeting Grants Funded | 4,316 | $2,174,188 | 4,211 | $2,424,517 |
| Competing Grants Funded | 1,224 | $640,639 | 964 | $651,505 |
| Administrative Supplements | 436 | $47,330 | 346 | $46,646 |
| Partial Assessment for DHHS Program Evaluation | $109,184 | $109,184 |
| Grant Category | R01 or Share | 2024 No. or % | 2024 Amount | 2025 No. or % | 2025 Amount |
|---|---|---|---|---|---|
| Grants within Paylines | 888 | $420,190 | 744 | $466,892 | |
| Traditional R01 | 616 | $347,693 | 529 | $405,797 | |
| RFA Grants | 108 | $79,166 | 63 | $64,107 | |
| Share of Competing Grant Funds | 12.4% | 9.8% | |||
| Exception Grants | 336 | $220,450 | 220 | $184,613 | |
| Share of Competing Grant Funds | 34.4% | 28.3% |
| Statistical Measure | 2024 | 2025 |
|---|---|---|
| Total Competing Application Requests* | 8,990 | 10,170 |
| Funding Success Rate | 14% | 9% |
| Percentile Funding for R01 Grants | 10th & 17th | 9th & 15th |
| Average Cost-Competing | $523 | $676 |
| Standard R01 non-modular reduction from Recommended/Requested Levels | -17% | -17% |
| *Excludes SBIR/STTR | ||
| Includes FY 2025 Cancer Moonshot funding. Excludes FY 2017 through FY2024 Moonshot carryover obligations. Traditional R01 line (Includes Trad R01 and converted R37) | ||
| **The interim FY 2025 R01 payline that was established while the Institute was operating under a continuing resolution was rescinded. No official R01 payline was established for FY 2025. In addition, an NIH multi-year funding policy was implemented in that fiscal year that allowed several RPG competing awards to be funded for the entire project period upfront. Due to these policy changes, the FY2025 payline awards, success rate, and average cost information are not comparable to those of previous fiscal years. | ||
RPGs Funding Mechanisms
The "Other" category includes DP1, DP2, DP5, R00, R37, U01, U19, UH2, UH3, UG3, UA5, R50, UM1, R15, R55, and R56 activities.
The interim R01 payline, which was established while the Institute was operating under a continuing resolution, was rescinded. No official R01 payline was established for FY 2025. In addition, an NIH multi-year funding policy was implemented in that fiscal year that allowed several RPG competing awards to be funded upfront for the entire project period. Due to these policy changes, the FY2025 awards are not comparable to those of previous fiscal years.
| RPG Mechanism | 2024 | 2025 | Description |
|---|---|---|---|
| R01 Traditional Grants | 10th & 17th | N/A | Percentile |
| P01 Program Projects | 17% Reduction | 17% Reduction | SPL Selected* |
| R03 Small Grants | 25 | 25 | Impact Score |
| R15 Academic Research | 25 | 25 | Impact Score |
| R21 Exploratory Phase I | 10th | 7th | Percentile |
| R33 Exploratory Phase II | N/A | N/A | SPL Selected* |
| R41/R42 STTR | 25 | 25 | Impact Score |
| R43/R44 SBIR | 25 | 27 | Impact Score |
| *SPL = Scientific Program Leaders (NCI) | |||
RPGs Requested and Awarded
The following table displays requested and awarded RPGs and their success rates for fiscal years 2024 and 2025. These numbers include Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards. The Download the Data link contains data for the prior ten years.
| Fiscal Year | Type | Number Requested | Amount Requested | Number Awarded | Amount Awarded | Success Rate |
|---|---|---|---|---|---|---|
| 2024 | Competing New | 10,064 | $5,589,733 | 1,177 | $608,278 | 12.6% |
| Competing Renewal | 419 | $360,938 | 145 | $100,450 | ||
| Competing Supplement | 8 | $2,005 | 3 | $515 | ||
| Competing Subtotal | 10,491 | $5,952,676 | 1,325 | $709,243 | ||
| Non-Competing | 4,414 | $2,311,369 | ||||
| FY 2024 RPG Total | 5,739 | $3,020,612 | ||||
| 2025 | Competing New | 11,243 | $6,354,078 | 950 | $612,433 | 9.4% |
| Competing Renewal | 464 | $415,712 | 148 | $133,444 | ||
| Competing Supplement | 4 | $878 | 0 | $0 | ||
| Competing Subtotal | 11,711 | $6,770,668 | 1,098 | $745,877 | ||
| Non- Competing | 4,211 | $2,471,163 | ||||
| FY 2025 RPG Total | 5,309 | $3,217,040 | ||||
| Includes FY 2023 Cancer Moonshot funding. Excludes FY 2017 through FY2022 Moonshot carryover obligations. | ||||||
The interim R01 payline, which was established while the Institute was operating under a continuing resolution, was rescinded. No official R01 payline was established for FY 2025. In addition, an NIH multi-year funding policy was implemented in that fiscal year that allowed several RPG competing awards to be funded upfront for the entire project period. Due to these policy changes, the FY2025 awards are not comparable to those of previous fiscal years. | ||||||
RPG Awards by Grant Activity Codes
This table displays data from awarded research project grants (RPG) by grant activity code and count. Please visit NIH Activity Codes for more information on the descriptions.
| Year | Total No. Awarded | Total Amount | Average Cost |
|---|---|---|---|
| 2015 | 4,767 | $2,019,308 | $424 |
| 2016 | 4,666 | $2,068,869 | $443 |
| 2017 | 4,663 | $2,195,184 | $471 |
| 2018 | 4,780 | $2,366,530 | $495 |
| 2019 | 4,984 | $2,456,156 | $493 |
| 2020 | 5,070 | $2,677,206 | $514 |
| 2021 | 5,221 | $2,739,345 | $525 |
| 2022 | 5,505 | $2,871,997 | $522 |
| 2023 | 5,736 | $3,037,911 | $530 |
| 2024 | 5,739 | $3,020,612 | $526 |
| 2025 | 5,401 | $3,304,237 | $612 |
| Grant Code | 2024 Number | 2024 Amount | 2025 Number | 2025 Amount |
|---|---|---|---|---|
| R01 | 3,698 | $1,842,927 | 3,439 | $2,037,543 |
| DP1 | 2 | $1,090 | 2 | $1,089 |
| DP2 | 0 | $20 | 0 | $0 |
| DP5 | 0 | $0 | 0 | $0 |
| P01 | 90 | $187,561 | 89 | $203,731 |
| R00 | 115 | $28,296 | 113 | $28,147 |
| R37 | 381 | $180,953 | 383 | $205,482 |
| U01 | 333 | $234,896 | 320 | $265,670 |
| U19 | 10 | $15,494 | 9 | $12,306 |
| U34 | 2 | $564 | 3 | $911 |
| UH2 | 4 | $937 | 7 | $1,564 |
| R34 | 15 | $4,384 | 20 | $7,183 |
| R35 | 120 | $112,120 | 111 | $109,233 |
| R50 | 111 | $19,286 | 129 | $27,598 |
| UH3 | 29 | $22,827 | 25 | $25,259 |
| UA5 | 0 | $0 | 0 | $0 |
| UM1 | 19 | $55,120 | 18 | $54,194 |
| UG3 | 18 | $16,176 | 25 | $17,380 |
| R03 | 102 | $10,375 | 86 | $9,794 |
| R21 | 395 | $96,400 | 283 | $74,105 |
| R33 | 47 | $16,996 | 54 | $20,378 |
| R15 | 20 | $9,213 | 22 | $10,382 |
| R55 | 0 | $0 | 0 | $0 |
| R56 | 4 | $1,006 | 1 | $242 |
| R61 | 25 | $5,515 | 36 | $10,478 |
| RC2 | 0 | $0 | 0 | $0 |
| SBIR/STTR | 199 | $158,454 | 226 | $181,570 |
| Total | 5,739 | $3,020,612 | 5,401 | $3,304,237 |